Full-Time
Develops therapies for rare diseases
$171k - $239.7k/yr
Senior, Expert
New York, NY, USA
Hybrid position requiring some in-office presence; travel within North America and internationally (10%-20%).
Insmed develops therapies for patients with serious and rare diseases. The company focuses on unmet medical needs and has a pipeline of clinical trials and approved treatments. Its products work by targeting specific conditions that currently lack effective treatments, and the company generates revenue through the sale of these therapies. Insmed stands out from competitors by its dedication to patient care and its global presence, with offices in the US, Europe, and Japan. The goal of Insmed is to address diverse healthcare challenges and improve the lives of patients with rare diseases.
Company Size
501-1,000
Company Stage
IPO
Headquarters
Richmond, Virginia
Founded
1988
Help us improve and share your feedback! Did you find this helpful?
Flexible Work Hours
Health Insurance
Paid Vacation
Employee Stock Purchase Plan
Company Equity
Insmed –Insmed Inc., a global biopharmaceutical company, Tuesday announced positive topline results from its Phase 2b study evaluating the efficacy and safety of treprostinil palmitil inhalation powder (TPIP), administered once daily in patients with pulmonary arterial hypertension (PAH).The results of the double-blind, placebo-controlled study demonstrated the durability of TPIP’s therapeutic effect as a once-daily therapy based on efficacy being evaluated about 24 hours after therapy was administered.Based on these results, Insmed will engage with the Food and Drug Administration regarding the Phase 3 trial design for pulmonary arterial hypertension. Insmed plans to initiate a Phase 3 trial in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) before the end of 2025 and a Phase 3 trial in patients with PAH in early 2026.Pulmonary arterial hypertension is a progressive, rare disease in which the blood vessels in the lungs narrow or become obstructed, leading to high blood pressure in the pulmonary arteries. The most common symptoms include shortness of breath, chest pain, dizziness or fainting, fatigue, and weakness. It is estimated that about 35,000 patients in the U.S. have been diagnosed with the disease. Untreated, PAH can be debilitating and often fatal.“The statistically significant and clinically meaningful results shown with TPIP in pulmonary arterial hypertension mark a potential breakthrough for patients and the future of prostanoid therapy,” said Gene Sullivan, chief product strategy officer of Insmed.The study was conducted at 44 sites globally; 102 patients were randomized to receive either TPIP or placebo for 16 weeks
BRIDGEWATER, N.J., April 29, 2025 /PRNewswire/ - Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the BofA Securities 2025 Health Care Conference in Las Vegas on Tuesday, May 13, 2025, at 2:20 p.m. PT.
Proficio Capital Partners LLC invests $1.86 million in Insmed Incorporated (NASDAQ:INSM).
BRIDGEWATER, N.J., Feb. 7, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 66 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.In connection with the commencement of their employment, the employees received options on February 3, 2025 to purchase an aggregate 108,860 shares of Insmed common stock at an exercise price of $77.88 per share, the closing trading price on the Nasdaq Global Select Market on the date of grant.The options have a 10-year term and a four-year vesting schedule, with 25% of the shares subject to the option vesting on the first anniversary of the relevant grant date and 12.5% of the shares subject to the option vesting every six months thereafter through the fourth anniversary of the relevant grant date, subject to the relevant employee's continued service with Insmed on the applicable vesting date.About InsmedInsmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company's early-stage research programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States, Europe, and Japan
--ARIKAYCE® (amikacin liposome inhalation suspension) Exceeds the Upper End of Guidance Range for Full-Year 2024 with Unaudited Global Revenues of Approximately $363.7 Million----2025 Global ARIKAYCE Revenues Expected to be Between $405 Million and $425 Million, Reflecting Continued Double-Digit Growth Compared to 2024----NDA for Brensocatib in Bronchiectasis Submitted to FDA in December 2024, Narrowing the Timing for Expected U.S. Launch to the Third Quarter of 2025, Pending Approval Under Priority Review----Enrollment for Phase 2 Study of TPIP in Patients with PAH Completed in December 2024; Expected Timing for Topline Data Moved Forward to Mid-2025----Phase 3 ENCORE Trial for ARIKAYCE in Patients with Newly Diagnosed or Recurrent MAC Lung Disease Fully Enrolled; Topline Data Anticipated in First Quarter of 2026----IND Cleared for Insmed's First Gene Therapy (INS1201) for Patients with DMD; First Patient Dosing Anticipated in the First Half of 2025--BRIDGEWATER, N.J., Jan. 10, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today provided an update on the Company's commercial and clinical programs and its outlook for 2025. These updates will be discussed as part of the Company's presentation at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 13, 2025, at 3:00 p.m. PT (6:00 p.m